Table 2.
Characteristics of the rapid guidelines according to organisations (n = 36)
| WHO (n = 8) |
NICE (n = 9) |
CDC (n = 17) |
Othersa (n = 12) |
|
|---|---|---|---|---|
| Number of recommendations per documentb | 11.6 (5–27) | 18.5 (12–40) | 6.9 (1–19) | 4.1 (1–53)c |
| Timeframe (months)b | 8.5 (5–12) | 21 (15–26) | NR | NR |
| New systematic reviews | 4 | 8 | NR | 1d |
| Quality of evidence assessment | Yes | Yes | NR | 1d |
| Economic analysis | No | Yes | No | No |
CDC United States Centers for Disease Control and Prevention, NICE National Institute for Health and Care Excellence, NR not reported, WHO World Health Organization
a Others include: American College of Medical Toxicology, Health Protection Agency Group A Streptococcus Working Group, International Society of Ultrasound in Obstetrics and Gynecology, Public Health Agency of Canada, the Royal College of Ophthalmologists (United Kingdom), Sociedad Española de Oncología Médica (Spanish Society of Medical Oncology), WHO Global Malaria Programme. In addition, one guideline published on behalf of the following organisations American Academy of Allergy, Asthma & Immunology; American Academy of Pediatrics; American College of Allergy, Asthma & Immunology; Australasian Society of Clinical Immunology and Allergy; Canadian Society of Allergy and Clinical Immunology; European Academy of Allergy and Clinical Immunology; Israel Association of Allergy and Clinical Immunology; Japanese Society for Allergology; Society for Pediatric Dermatology; and World Allergy Organization
b Median (range)
c 1 not reported
d 11 not reported